theranosfilm / independent analysis

Research / primary records and open questions

What did Theranos patent—and what did it prove?

A first claim-by-claim map of US8283155B2 distinguishes protected architecture from evidence of clinical performance.

Edited by the Theranos Film project · Briar assisted · . Editorial draft; not independently fact-checked. About this independent project · Corrections and review history.

Current evidence status

Granted-claim reading; product implementation and legal title not verified

The granted claim's centre

Claim 1 concerns a two-way communication system: a reader, an external protocol source and an identified test device with a sample collector and assay reactants. Dependent claim 9 adds collection below about 500 microlitres. That limit is not itself a claim that all tests run from one drop.

Sources and inspection limits
  • US8283155B2: Point-of-care fluidic systems and uses thereof · Original source

    Granted patent record · Bibliographic record; granted claims 1–10, especially 1 and 9

    Selected granted claims and original-assignee/publication fields inspected on 21 November 2026; no validity or legal-title audit. A granted patent is not regulatory clearance or clinical validation; product-to-claim mapping remains unverified. Database ownership labels are not a legal opinion.

Correct or challenge this entry · Curated revision history

Ownership and dates need their own evidence

The record lists Theranos as original assignee and 9 October 2012 as the grant publication date. Later database ownership labels do not establish legal title at every investment date. Check the assignment instruments and prosecution history before making an ownership, validity or freedom-to-operate conclusion.

Sources and inspection limits
  • US8283155B2: Point-of-care fluidic systems and uses thereof · Original source

    Granted patent record · Bibliographic record; granted claims 1–10, especially 1 and 9

    Selected granted claims and original-assignee/publication fields inspected on 21 November 2026; no validity or legal-title audit. A granted patent is not regulatory clearance or clinical validation; product-to-claim mapping remains unverified. Database ownership labels are not a legal opinion.

Correct or challenge this entry · Curated revision history

Architecture is not validation

A claim can define an invention without proving that a commercial device implemented it reliably, met a clinical acceptance criterion, delivered a broad menu or justified an investor representation. Product mapping below is deliberately unverified rather than inferred from a similar diagram.

Project process or technical interpretation; no external source is cited for this paragraph.

Correct or challenge this entry · Curated revision history

A first granted-claim chart

These are concise paraphrases, not replacement claim language or a legal opinion. Read the complete granted wording and dependencies.

US8283155B2: selected elements and unverified implementation
ClaimElementProduct evidence
1(a)Programmable reader linked to a communications assembly.
US8283155B2, claim 1(a)
Unverified: needs the dated reader design and software record.
1(b)External device transmits a protocol.
Claim 1(b)
Unverified: identify the external device and actual protocol exchange.
1(c)(i–ii)Inserted test device collects fluid and contains assay reactants.
Claim 1(c)(i–ii)
Unverified: identify cartridge, sample path and reagents—not just a similar enclosure.
1(c)(iii)Device identifier triggers selection/transmission of the protocol.
Claim 1(c)(iii)
Unverified: needs identifier behaviour and protocol-selection evidence.
1, final clauseProtocol governs reaction/detection; measured signal returns externally.
Claim 1, final wherein clause
Unverified: signal communication is not proof of accuracy, throughput or a clinical menu.
9, dependent on 1Collection below about 500 microlitres.
Claim 9
Unverified: this collection limit does not establish usable volume for every advertised assay.
Sources and inspection limits

Review this claim chart · Technology and validation explanation

What is still needed

Read the curated dossier JSON · Inspect the full source register